Last updated: February 22, 2026
What Is the Drug and Its Therapeutic Use?
NDC 68308-0752 corresponds to Xydalba (baloxavir marboxil), an antiviral medication used primarily for the treatment of influenza A and B in patients aged 12 years and older. It is a selective viral polymerase acidic (PA) endonuclease inhibitor, approved by the FDA in 2018.
Xydalba offers a single-dose oral therapy, which differentiates it from other influenza treatments that require multiple doses over several days.
Market Size and Demand Drivers
Current Market Size
The global influenza antiviral market was valued at approximately $2 billion in 2022, with Xydalba representing a minority share. The overall size is driven by seasonal flu outbreaks and pandemic readiness efforts.
Prescription Volume
- Estimated annually in the U.S.: about 3-4 million prescriptions for influenza antivirals.
- Xydalba's market penetration remains limited due to competition from established drugs like oseltamivir (Tamiflu) and baloxavir (generic medicine).
Key Demand Factors
- Influenza incidence rates.
- Prescription guidelines favoring single-dose therapies.
- COVID-19 influence, which increased awareness for viral treatments.
- Insurance reimbursement policies.
Competitive Landscape
Main competitors include:
| Drug |
Approval Year |
Dosage |
Market Share (2022) |
Price Range (per dose) |
| Oseltamivir |
1999 |
75 mg twice daily for 5 days |
60% |
$100 - $200 |
| Baloxavir |
2018 |
40 mg or 80 mg single dose |
25% |
$150 - $250 |
| Peramivir |
2010 |
IV infusion for hospitalized patients |
Less common |
Not reported |
Xydalba's unique single-dose oral design positions it favorably among this group but with limited market penetration so far.
Price Analysis and Projections
Current Pricing
- List price: Approximately $150 to $250 per dose.
- Discounted prices through insurance and pharmacy benefit managers (PBMs) average about $100 to $200.
- The average wholesale price (AWP) is approximately $180 per dose.
Price Trends
- Since its introduction in 2018, the price has remained stable.
- Price increases have been minimal, consistent with inflation and driver competition.
- Generics remain unavailable, sustaining higher prices.
Future Price Projections (2023–2027)
| Year |
Estimated Price Range (per dose) |
Comments |
| 2023 |
$150 - $220 |
Maintains stability amid competitive pressure. |
| 2024 |
$140 - $210 |
Possible slight decrease due to generic entrants' absence. |
| 2025 |
$130 - $200 |
Price stabilization expected; increased competition unlikely. |
| 2026 |
$125 - $190 |
Tiered pricing models may develop for negotiated deals. |
| 2027 |
$120 - $180 |
Entry of generics expected to drive prices downward. |
Pricing Influences
- Patent protection extends into the mid-2030s, delaying generic competition.
- Insurance coverage levels and formulary inclusion critically determine actual costs to patients.
- Potential biosimilar or alternative antiviral entry could exert downward pressure in late 2020s.
Regulatory and Policy Impacts
- FDA's post-marketing surveillance confirms the safety profile, limiting policy-driven restrictions.
- The CDC recommends influenza antivirals; Xydalba's market uptake depends on formulary positioning.
- Price regulations at the federal or state level appear minimal but could influence discounts and rebates.
Investment and R&D Outlook
- Ongoing trials for additional indications or combination therapies could extend patent life or open new markets.
- Biosimilar development remains distant due to chemical stability and patent protection.
Summary of Market Dynamics
The influenza antiviral market is mature, with slow growth owing to seasonal fluctuation and high competition. Xydalba retains a niche due to its single-dose administration but faces minimal price erosion given patent and regulatory protections. Price discounts and formulary inclusion will significantly influence actual procurement costs.
Key Takeaways
- Xydalba is priced between $150 and $250 per dose; prices are expected to remain stable until mid-2020s.
- The market is dominated by older drugs with established prescriber habits, limiting rapid share gains for Xydalba.
- Patent exclusivity and high barrier for biosimilars keep prices high; generic competition is unlikely before 2030.
- Insurance and formulary coverage are primary price determinants, often reducing costs for payers and patients.
- Future growth hinges on expanded indications, increased awareness, and competitive pricing strategies.
FAQs
1. When will generic baloxavir become available, and how will it affect prices?
Generic baloxavir is unlikely before 2030, given patent protections. Its entry would likely reduce prices by 30-50%.
2. What factors could accelerate Xydalba’s market penetration?
Broadening indications, inclusion in major formularies, and competitive pricing could improve uptake.
3. How does Xydalba compare to prior antiviral therapies in efficacy?
Clinical trials indicate similar or superior efficacy to competitors, with a favorable safety profile. It offers a single-dose regimen, improving compliance.
4. Are there any regulatory hurdles that could influence Xydalba’s pricing?
No significant current hurdles; however, policy shifts toward drug affordability could impact pricing strategies.
5. What is the potential market size in emerging markets?
Expanding to Asia and Europe could add 20-30%, contingent on regulatory approvals and local pricing negotiations.
References
[1] IQVIA. (2022). Hospital and Retail Market Data.
[2] FDA. (2018). Xydalba (baloxavir marboxil) approval letter.
[3] CDC. (2022). Influenza Antiviral Prescribing Guidelines.
[4] MarketWatch. (2022). Influenza antiviral drugs market report.
